IBC Life Sciences, Sheraton National Hotel, Arlington, VA
June 24-25, 2004
The proven success of FDA’s PAT initiative in the pharmaceutical industry will have a tremendous effect on the manufacturing of biologics in the near future. IBC’s Process Analytical Technologies for Biologics offers you a rare opportunity to hear the leading regulatory and industry experts. By attending you will learn why recent advances in biotech have recently increased the need for process analytical technologies to assist in the monitoring and control of bioprocesses. Our goal is to make it even easier for you to adopt PAT into your biopharmaceutical manufacturing facilities. Experts will show you how to apply process analytical technologies to enhance the economics and quality of your biotechnology products. For detailed abstracts and up-to-date information on this event, visit www.LifeSciencesInfo.com/PAT or call +1 (508) 616-5550.
|
|
|
Invited Speakers:
|
|
Featured Presenters: Keith O. Webber, Ph.D., Acting Director, Office of Biotechnology Products, CDER, FDA PAT for Recombinant Biologics in CDER Chris Joneckis, Ph.D., Senior Advisor for Chemistry Manufacturing and Control Issues, Office of the Director, CBER, FDA FDA
Perspectives on the PAT Initiative for Biologics William Egan, Ph.D., Acting Director, Office of Vaccines Research and Reviews, CBER, FDA
A CBER Perspective on Rapid Microbial Tests Jerry Cacia, Associate Director of Recovery Manufacturing Science and Technology, Genentech, Inc.
Strategies for Monitoring and Controlling Production of Recombinant Proteins Shuhong Zhang, Ph.D., Manager, Global Biologics Analytical R&D, Pfizer
Applying the PAT Concept to Support Process Development and Large-Scale Manufacturing of a Glycoprotein: UK-279, 276
|
|